Login | New Member? Signup Free
ChangeDetect » News

USPTO Issues Notice of Allowance to Proterro for Composition of Matter Patent Protecting Proterro’s Engineered

EWING, N.J.—-Proterro, the only company making sugar rather than extracting it from crops, has received notice of allowance from USPTO on a composition of matter patent that is the cornerstone of its IP portfolio.

Tags: , , , , , ,

USPTO issues patent to QRxPharma’s MoxDuo for treatment of acute and chronic pain

QRxPharma Limited announced today that the United States Patent and Trademark Office issued the Company U.S. Patent No. 8,182,837, which does not expire until 2023.

Tags: , , , , , , , , , , ,

USPTO issues patent to MicuRx’s MRX-I antibacterial agent

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone that targets infections due to multi-drug resistant Gram-positive pathogens.

Tags: , , , , , , , , , , , , , ,

USPTO issues patent to Tris Pharma’s OralXR+ platform

Tris Pharma, an emerging specialty pharmaceutical company, announced the US grant of its core technology patent for its OralXR+ platform. This is the first patent grant of a substantial estate filed by Tris Pharma and covers a multitude of actives having modified release formulations comprising drug-ion exchange resin complexes.

Tags: , , , , , , , ,

USPTO issues patent to Novus Scientific’s TIGR Matrix Surgical Mesh

The Intellectual Property portfolio of TIGR Matrix Surgical Mesh has been further complimented with the granting of a second U.S. patent related to material degradation and mechanical behaviour.

Tags: , , , , , , ,

USPTO issues patent to Rexahn’s new anti-cancer arylisoquinolinamine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled “5, 6, or 7-Substituted-3- arylisoquinolinamine derivatives and therapeutic use thereof.”

Tags: , , , , , , , , , , , ,

USPTO issues notice of allowance to PROLOR Biotech’s CTP platform

PROLOR Biotech, Inc., today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application covering the company’s CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins. (4 hours ago)

Tags: , , , , , , , , , ,